Trump Administration Plans to End Medicare Drug Plan Subsidy, Affecting Premium Costs
The Trump administration has announced plans to terminate a subsidy program that has been instrumental in keeping premiums for Medicare drug plans affordable. According to the Wall Street Journal, the program, which is expected to provide insurers with approximately $3.6 billion in subsidies this year, will not be renewed beyond 2026. Medicare Part D, which offers prescription drug coverage to millions of Medicare beneficiaries through private insurance plans, is a crucial component of the federal health program for seniors. Rising healthcare costs are a significant concern in the U.S., especially for older Americans living on fixed incomes. Nearly 25 million people were enrolled in standalone Medicare Part D prescription drug plans in 2026, as reported by the health policy research group KFF. An administration official stated that the subsidies encouraged insurers to raise premiums, as the government absorbed much of the added cost. The official also mentioned that other measures aimed at controlling Medi... 
